Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
Trial ID or NCT#
NCT02000102
Status
NOT RECRUITING
Purpose
Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
- Those patients with diabetic macular edema switched to aflibercept from bevacizumab and/or ranibizumab -
Exclusion Criteria:
- None
- -
Investigator(s)
Theodore Leng, MD, FACS
Ophthalmologist
Professor of Ophthalmology (Ophthalmology Research/Clinical Trials) and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (MSD)
Contact us to find out if this trial is right for you.
Contact
Theodore Leng, MD
650-723-6995
View on